Who Benefit From Essential Drug Price Control, Need of Price Control In India -A review
Keywords:
Essential medicine, NPPA, Pharmaceutical IndustryAbstract
As countries become wealthier, they typically experience an epidemiological transition and pressures on public healthcare budgets grow, with healthcare commodities, especially pharmaceuticals, contributing a large share of increases in both government and individual household spending. Procurement effectiveness and efficiency become, therefore, all the more important, with pharmaceutical and device pricing policies central in national and global strategies for healthcare system reform and strengthening. India is one of the developing countries. A substantial proportion of population of this country is largely exposed to the drug market whose purchasing power is extremely low. Around 42% population of this country lives under the National poverty line ($1.9 per day). Vital issue concerning them is to access the health care facility at an affordable cost. Medicine is a part of health care cost and it costs to around 70% to 80% of total cost. Thus, cost of medicine is a governing factor of health care system especially when it comes to price control of health care facilities. To bring down the cost of health care facilities, government spends money for health care facilities. A comparative expenditure made by state government is depicted in this article. NPPA (National Pharmaceutical Pricing Authority) is the Indian pharmaceutical pricing regulating authority and it achieves its objectives by implementing the DPCO (Drug Pricing control order). In spite of existence of the DPCO, drastic price variation is observed between the products of same API (Active Pharmaceutical Ingredient) and several factors are responsible for the same. To overcome the stated problem and monopolistic trade practice by patent holder/brand manufacturer, TRIPS (Trade Related Intellectual Properties Rights) provides Compulsory Licenses which has its unique role to play in affordability of medicines. This study will thus try to justify the need to bring NLEM Indian pharmaceutical sector is rising very rapidly and there is a want of regulatory affairs.
References
Sakthivel Selvaraj, (2007), How Effective Is India’s Drug Price Control Regime?
[Internet]. [cited 2013 Dec] Available from: http://www.hsph.harvard.edu/takemi/files/2012/10/ RP256.pdf
Human Development Report 2010 - 20th Anniversary Edition, Chapter 5 innovations in measuring inequality and poverty. [Internet]. [cited 2013 Dec] Available from: http://origin- hdr.undp.org/en/media/HDR_2010_EN_Chapter5_r eprint.pdf
Times of India online - Govt. to bring essential medicines under price control, Kounteya Sinha. Sep. 28, 2012. [Internet]. [cited 2013 Dec] Available from: http://articles.timesofindia.indiatimes.com/2012-09- 28/india/34147534_1_price-control-nlem-essential- medicines
Competition Law and Indian Pharmaceutical Industry, Centre for Trade and Development (Centad), New Delhi 2010, [Internet]. [cited 2013 Dec] Available from:www.cci.gov.in/images/media/completed/PharmInd 230611.pdf
Function of National Pharmaceutical Pricing Authority, [Internet]. [cited 2013 Dec] Available from:
http://www.nppaindia.nic.in/index1.html
Govt. of India (2005b), Report of the Task Force to Explore Options Other Than Price Control for Achieving the Objective of Making Available Life- Saving Drugs At Reasonable Prices”, September, 20, pp.17. [Internet]. [cited 2013 Dec] Available from:
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.